tiprankstipranks
Trending News
More News >
Esperion (ESPR)
NASDAQ:ESPR
US Market

Esperion (ESPR) Stock Forecast & Price Target

Compare
1,547 Followers
See the Price Targets and Ratings of:

ESPR Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
3 Buy
1 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Esperion
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ESPR Stock 12 Month Forecast

Average Price Target

$5.77
▲(372.95%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Esperion in the last 3 months. The average price target is $5.77 with a high forecast of $16.00 and a low forecast of $1.85. The average price target represents a 372.95% change from the last price of $1.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","-1":"-$1","3.5":"$3.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,2.08,3.2399999999999998,4.3999999999999995,5.56,6.72,7.879999999999999,9.04,10.2,11.36,12.52,13.68,14.839999999999998,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,1.293076923076923,1.666153846153846,2.039230769230769,2.4123076923076923,2.7853846153846153,3.158461538461538,3.531538461538461,3.904615384615384,4.277692307692307,4.650769230769231,5.023846153846153,5.396923076923076,{"y":5.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,0.9915384615384616,1.063076923076923,1.1346153846153846,1.2061538461538461,1.2776923076923077,1.3492307692307692,1.4207692307692308,1.4923076923076923,1.5638461538461539,1.6353846153846154,1.706923076923077,1.7784615384615385,{"y":1.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.16,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$5.77Lowest Price Target$1.85
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ESPR
TipRanks AITipRanks
Not Ranked
TipRanks
$1
Hold
-18.03%
Downside
Upgraded
06/06/25
Esperion's overall stock score is driven primarily by its robust revenue growth and positive shareholder sentiment. However, the score is significantly constrained by ongoing financial challenges, including negative profitability and high leverage. Technical indicators suggest some positive momentum, but valuation remains a concern due to the lack of earnings and dividends.
H.C. Wainwright Analyst forecast on ESPR
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$16
Buy
1211.48%
Upside
Reiterated
06/03/25
Esperion's Strategic Positioning and Growth Potential: Legal Settlements and Market Expansion Drive Buy Rating
Needham
$5$4
Buy
227.87%
Upside
Reiterated
05/06/25
Esperion's Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances
Bank of America Securities Analyst forecast on ESPR
Jason ZemanskyBank of America Securities
Bank of America Securities
$1.85
Sell
51.64%
Upside
Reiterated
04/23/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)
Goldman Sachs Analyst forecast on ESPR
Paul ChoiGoldman Sachs
Goldman Sachs
$4$3
Hold
145.90%
Upside
Reiterated
04/16/25
Esperion Therapeutics (ESPR) PT Lowered to $3 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $3.00 (from $4.00) while maintaining a Neutral rating.
Citizens JMP Analyst forecast on ESPR
Jason ButlerCitizens JMP
Citizens JMP
$4
Buy
227.87%
Upside
Reiterated
03/24/25
Esperion's Strategic Growth: Phase 3 Expansion and Patent Protection Boost Valuation
BTIG
$9
Buy
637.70%
Upside
Reiterated
03/04/25
Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
Cantor Fitzgerald Analyst forecast on ESPR
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$8
Buy
555.74%
Upside
Initiated
12/17/24
Cantor Fitzgerald starts Esperion Therapeutics (ESPR) at OverweightCantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Overweight rating and a price target of $8.00.
Jefferies Analyst forecast on ESPR
Dennis DingJefferies
Jefferies
$5
Buy
309.84%
Upside
Reiterated
12/10/24
Esperion's Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol Competition
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ESPR
TipRanks AITipRanks
Not Ranked
TipRanks
$1
Hold
-18.03%
Downside
Upgraded
06/06/25
Esperion's overall stock score is driven primarily by its robust revenue growth and positive shareholder sentiment. However, the score is significantly constrained by ongoing financial challenges, including negative profitability and high leverage. Technical indicators suggest some positive momentum, but valuation remains a concern due to the lack of earnings and dividends.
H.C. Wainwright Analyst forecast on ESPR
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$16
Buy
1211.48%
Upside
Reiterated
06/03/25
Esperion's Strategic Positioning and Growth Potential: Legal Settlements and Market Expansion Drive Buy Rating
Needham
$5$4
Buy
227.87%
Upside
Reiterated
05/06/25
Esperion's Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances
Bank of America Securities Analyst forecast on ESPR
Jason ZemanskyBank of America Securities
Bank of America Securities
$1.85
Sell
51.64%
Upside
Reiterated
04/23/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)
Goldman Sachs Analyst forecast on ESPR
Paul ChoiGoldman Sachs
Goldman Sachs
$4$3
Hold
145.90%
Upside
Reiterated
04/16/25
Esperion Therapeutics (ESPR) PT Lowered to $3 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $3.00 (from $4.00) while maintaining a Neutral rating.
Citizens JMP Analyst forecast on ESPR
Jason ButlerCitizens JMP
Citizens JMP
$4
Buy
227.87%
Upside
Reiterated
03/24/25
Esperion's Strategic Growth: Phase 3 Expansion and Patent Protection Boost Valuation
BTIG
$9
Buy
637.70%
Upside
Reiterated
03/04/25
Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
Cantor Fitzgerald Analyst forecast on ESPR
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$8
Buy
555.74%
Upside
Initiated
12/17/24
Cantor Fitzgerald starts Esperion Therapeutics (ESPR) at OverweightCantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Overweight rating and a price target of $8.00.
Jefferies Analyst forecast on ESPR
Dennis DingJefferies
Jefferies
$5
Buy
309.84%
Upside
Reiterated
12/10/24
Esperion's Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol Competition
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Esperion

1 Month
xxx
Success Rate
9/17 ratings generated profit
53%
Average Return
+8.89%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +8.89% per trade.
3 Months
xxx
Success Rate
8/17 ratings generated profit
47%
Average Return
+3.38%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +3.38% per trade.
1 Year
Success Rate
7/23 ratings generated profit
30%
Average Return
+8.65%
reiterated a buy rating 3 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of +8.65% per trade.
2 Years
xxx
Success Rate
4/17 ratings generated profit
24%
Average Return
-26.95%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -26.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ESPR Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
11
12
11
12
7
Buy
0
0
0
0
0
Hold
1
0
1
1
1
Sell
4
5
3
2
1
Strong Sell
0
0
0
0
0
total
16
17
15
15
9
In the current month, ESPR has received 7 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. ESPR average Analyst price target in the past 3 months is 5.77.
Each month's total comprises the sum of three months' worth of ratings.

ESPR Financial Forecast

ESPR Earnings Forecast

Next quarter’s earnings estimate for ESPR is -$0.15 with a range of -$0.19 to -$0.09. The previous quarter’s EPS was -$0.21. ESPR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year ESPR has Outperformed its overall industry.
Next quarter’s earnings estimate for ESPR is -$0.15 with a range of -$0.19 to -$0.09. The previous quarter’s EPS was -$0.21. ESPR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year ESPR has Outperformed its overall industry.

ESPR Sales Forecast

Next quarter’s sales forecast for ESPR is $62.55M with a range of $53.40M to $71.80M. The previous quarter’s sales results were $65.00M. ESPR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ESPR has Outperformed its overall industry.
Next quarter’s sales forecast for ESPR is $62.55M with a range of $53.40M to $71.80M. The previous quarter’s sales results were $65.00M. ESPR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ESPR has Outperformed its overall industry.

ESPR Stock Forecast FAQ

What is ESPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Esperion’s 12-month average price target is 5.77.
    What is ESPR’s upside potential, based on the analysts’ average price target?
    Esperion has 372.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ESPR a Buy, Sell or Hold?
          Esperion has a consensus rating of Moderate Buy which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Esperion’s price target?
            The average price target for Esperion is 5.77. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $1.85. The average price target represents 372.95% Increase from the current price of $1.22.
              What do analysts say about Esperion?
              Esperion’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of ESPR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis